S&P 500   4,266.40 (-0.50%)
DOW   33,317.12 (-0.57%)
QQQ   359.47 (+0.33%)
AAPL   173.11 (+1.11%)
MSFT   319.42 (+1.16%)
META   304.30 (+1.36%)
GOOGL   133.27 (+1.84%)
AMZN   128.95 (+1.44%)
TSLA   249.08 (-0.46%)
NVDA   445.68 (+2.46%)
NIO   8.76 (-3.10%)
BABA   86.20 (-0.62%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.27 (-1.21%)
MU   67.49 (-0.79%)
CGC   0.74 (-5.75%)
GE   108.58 (-1.78%)
DIS   81.37 (+0.39%)
AMC   8.09 (+1.25%)
PFE   33.75 (+1.75%)
PYPL   58.57 (+0.19%)
NFLX   380.01 (+0.64%)
S&P 500   4,266.40 (-0.50%)
DOW   33,317.12 (-0.57%)
QQQ   359.47 (+0.33%)
AAPL   173.11 (+1.11%)
MSFT   319.42 (+1.16%)
META   304.30 (+1.36%)
GOOGL   133.27 (+1.84%)
AMZN   128.95 (+1.44%)
TSLA   249.08 (-0.46%)
NVDA   445.68 (+2.46%)
NIO   8.76 (-3.10%)
BABA   86.20 (-0.62%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.27 (-1.21%)
MU   67.49 (-0.79%)
CGC   0.74 (-5.75%)
GE   108.58 (-1.78%)
DIS   81.37 (+0.39%)
AMC   8.09 (+1.25%)
PFE   33.75 (+1.75%)
PYPL   58.57 (+0.19%)
NFLX   380.01 (+0.64%)
S&P 500   4,266.40 (-0.50%)
DOW   33,317.12 (-0.57%)
QQQ   359.47 (+0.33%)
AAPL   173.11 (+1.11%)
MSFT   319.42 (+1.16%)
META   304.30 (+1.36%)
GOOGL   133.27 (+1.84%)
AMZN   128.95 (+1.44%)
TSLA   249.08 (-0.46%)
NVDA   445.68 (+2.46%)
NIO   8.76 (-3.10%)
BABA   86.20 (-0.62%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.27 (-1.21%)
MU   67.49 (-0.79%)
CGC   0.74 (-5.75%)
GE   108.58 (-1.78%)
DIS   81.37 (+0.39%)
AMC   8.09 (+1.25%)
PFE   33.75 (+1.75%)
PYPL   58.57 (+0.19%)
NFLX   380.01 (+0.64%)
S&P 500   4,266.40 (-0.50%)
DOW   33,317.12 (-0.57%)
QQQ   359.47 (+0.33%)
AAPL   173.11 (+1.11%)
MSFT   319.42 (+1.16%)
META   304.30 (+1.36%)
GOOGL   133.27 (+1.84%)
AMZN   128.95 (+1.44%)
TSLA   249.08 (-0.46%)
NVDA   445.68 (+2.46%)
NIO   8.76 (-3.10%)
BABA   86.20 (-0.62%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.27 (-1.21%)
MU   67.49 (-0.79%)
CGC   0.74 (-5.75%)
GE   108.58 (-1.78%)
DIS   81.37 (+0.39%)
AMC   8.09 (+1.25%)
PFE   33.75 (+1.75%)
PYPL   58.57 (+0.19%)
NFLX   380.01 (+0.64%)
NASDAQ:FLDM

Fluidigm (FLDM) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$3.27
$3.99
52-Week Range
N/A
Volume
60,126 shs
Average Volume
968,838 shs
Market Capitalization
$283.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

FLDM stock logo

About Fluidigm (NASDAQ:FLDM) Stock

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.


FLDM Stock News Headlines

Standard BioTools (NASDAQ: FLDM)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
No. 14 2022 Share trading in Solar A/S - Yahoo Finance UK
Standard BioTools Inc. Announc - GuruFocus.com
See More Headlines
Receive FLDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fluidigm and its competitors with MarketBeat's FREE daily newsletter.

FLDM Company Calendar

Last Earnings
11/07/2021
Today
10/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical Instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:FLDM
CUSIP
34385P10
Employees
615
Year Founded
N/A

Profitability

Net Income
$-59,240,000.00
Pretax Margin
-48.75%

Debt

Sales & Book Value

Annual Sales
$130.58 million
Book Value
$1.24 per share

Miscellaneous

Free Float
74,268,000
Market Cap
$283.76 million
Optionable
Optionable
Beta
1.14
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Stephen Christopher Linthwaite (Age 49)
    Pres, CEO & Director
    Comp: $1.2M
  • Mr. Vikram Jog (Age 66)
    Chief Financial Officer
    Comp: $667.25k
  • Mr. Bradley Allen Kreger (Age 47)
    Sr. VP of Global Operations
    Comp: $560.62k
  • Mr. Nicholas S. Khadder (Age 48)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $481.58k
  • Mr. Colin McCracken (Age 48)
    Chief Commercial Officer
    Comp: $734.78k
  • Dr. Stephen R. Quake D.phil. (Age 52)
    Ph.D., Co-Founder & Chairman of Advisory Board
  • Mr. Andrew Quong
    Chief Science Officer
  • Mr. Peter DeNardo
    Investor Relations
  • Mark Spearman
    Sr. Director of Corp. Communications
  • Ms. Angela Peters
    Chief HR Officer













FLDM Stock - Frequently Asked Questions

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) issued its quarterly earnings data on Sunday, November, 7th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.04. The medical research company had revenue of $28.50 million for the quarter. Fluidigm had a negative trailing twelve-month return on equity of 40.15% and a negative net margin of 45.36%. During the same quarter last year, the company earned ($0.03) earnings per share.

What is Chris Linthwaite's approval rating as Fluidigm's CEO?

30 employees have rated Fluidigm Chief Executive Officer Chris Linthwaite on Glassdoor.com. Chris Linthwaite has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Fluidigm own?
What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How much money does Fluidigm make?

Fluidigm (NASDAQ:FLDM) has a market capitalization of $0.00 and generates $130.58 million in revenue each year. The medical research company earns $-59,240,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Fluidigm have?

The company employs 615 workers across the globe.

How can I contact Fluidigm?

Fluidigm's mailing address is 2 Tower Place Ste 2000, South San Francisco CA, 94080. The official website for the company is www.fluidigm.com. The medical research company can be reached via phone at (650) 266-6000, via email at agnes.lee@fluidigm.com, or via fax at 650-871-7152.

This page (NASDAQ:FLDM) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -